Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
257 studies found for:    "Diabetic Nephropathies"

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Enrolling by invitation Mechanisms of Diabetic Nephropathy in Ecuador
Conditions: Diabetic Nephropathy;   Diabetes Mellitus;   Kidney Diseases;   Diabetic Kidney Disease;   Chronic Kidney Disease
Intervention:
2 Completed Spironolactone in Diabetic Nephropathy
Condition: Diabetic Nephropathy
Intervention: Drug: Spironolactone
3 Active, not recruiting Minocycline and Proteinuria in Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: Minocycline 100 mg po bid for 6 months;   Drug: placebo
4 Recruiting Resveratrol's Effects in Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: Resveratrol;   Drug: Placebo;   Drug: Losartan
5 Completed Soy Protein in Early Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Diabetes Mellitus
Intervention: Drug: soy protein
6 Active, not recruiting Glutathione in Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Proteinuria;   Oxidative Stress
Interventions: Drug: N-acetylcysteine placebo + silibin placebo;   Drug: N-acetylcysteine active + silibin placebo;   Drug: N-acetylcysteine placebo + silibin active;   Drug: N-acetylcysteine active + silibin active;   Drug: N-acetylcysteine active + high-dose silibin active
7 Completed Renal Denervation in Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Persistent Proteinuria With Type II Diabetes
Interventions: Procedure: Percutaneous renal denervation and TMNS;   Drug: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
8 Unknown † Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
Conditions: Diabetic Nephropathy;   Chronic Kidney Disease
Intervention: Drug: Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
9 Completed Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
Condition: Diabetic Nephropathy
Intervention: Drug: spironolactone
10 Terminated Effect of Sulodexide in Overt Diabetic Nephropathy
Condition: Diabetic Nephropathy
Intervention: Drug: Sulodexide
11 Completed Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
Conditions: Diabetic Nephropathy;   Chronic Kidney Disease;   Diabetes Type 2
Intervention: Drug: N-acetylcysteine
12 Completed N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
Conditions: Diabetic Nephropathies;   Proteinuria;   Oxidative Stress
Interventions: Dietary Supplement: N-acetylcysteine;   Dietary Supplement: silibin;   Dietary Supplement: high-dose silibin;   Dietary Supplement: N-acetylcysteine placebo;   Dietary Supplement: silibin placebo
13 Completed Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: Sevelamer Carbonate;   Drug: Calcium Carbonate
14 Completed Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients
Conditions: Diabetic Nephropathy;   Medication Compliance
Interventions: Other: low GI;   Other: conventional diet
15 Completed The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy
Condition: Diabetic Nephropathy
Intervention:
16 Completed Adiponectin and Insulin Resistance in Diabetic Nephropathy
Condition: Diabetic Nephropathy
Intervention: Drug: Losartan
17 Recruiting Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: MT-3995 Low;   Drug: MT-3995 Middle;   Drug: MT-3995 High;   Drug: Placebo
18 Completed Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
Conditions: Albuminuria;   Diabetic Nephropathy
Intervention: Drug: XL784
19 Completed Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.
Conditions: Chronic Kidney Disease;   Diabetic Nephropathy
Intervention: Behavioral: Community-based Integrated CKD Care
20 Completed Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy
Condition: Diabetic Nephropathy
Interventions: Drug: MT-3995-Low;   Drug: MT-3995-High;   Drug: Placebo
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years